LORVIQUA® (lorlatinib) as monotherapy is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on alectinib or ceritinib as the first ALK TKI therapy, or crizotinib and at least one other ALK TKI therapy1
ORR,PFS,DoR Individual Responses Prior ALK TKI CNS Efficacy
Guidelines ALK Resistance Mutations

​​​​​​​LORVIQUA® achieved frequent and durable responses in patients previously  treated with 2nd-generation ALK TKIs2,3​​​​​​​
ORR, PFS, and DoR results for patients treated with prior ALK  TKIs3
Adapted from the LORVIQUA SmPC. 2020.
Data cutoff:  February 2, 2018.4

*Patients predominantly received either alectinib or ceritinib as the last ALK TKI ± CT before LORVIQUA®.2 
† Objective tumor response (defined as complete response or partial response) according to RECIST version 1.1, as assessed by ICR2

Healthcare Professionals only

ALK+, Anaplastic lymphoma kinase positive; CI, confidence interval ; CNS, central  nervous system; CR, complete response; CT, chemotherapy; DoR, duration of response; ICR, independent central review;  N R,  not reached;  ORR, objective response rate; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine  kinase   inhibitor.
1. Pfizer. LORVIQUA® (lorlatinib) Prescribing Information, Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12540 Accessed September 23,2021. 
2. Solomon BJ, Besse B, Bauer TM, et at Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654-1667. 
3. Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics. December 2020. 
4. Besse B, Solomon Bl, Felip E, et al Lorlatinib in patients with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. Poster presented at the American Society of Clinical Oncology (ASCO); 1-5 June 2018: Chicago, IL, USA. ​​​​​​​
The use of lorlatinib has been associated with increases in serum cholesterol and triglycerides. Serum cholesterol and triglycerides should be monitored before the initiation of lorlatinib; 2, 4, and 8 weeks after initiating lorlatinib, and periodically thereafter. Initiation, or increase in the dose, of lipid-lowering agents is required.
Central nervous system (CNS) effects have been observed in patients receiving lorlatinib including seizures, psychotic effects, changes in cognitive function, mood (including suicidal ideation), mental status, sleep, and speech. Dose modification or discontinuation may be required for those patients who develop CNS effects.
PR interval prolongation and atrioventricular (AV) block events have been reported in patients receiving lorlatinib. Monitor electrocardiogram (ECG) prior to initiating lorlatinib and monthly thereafter, particularly in patients with predisposing conditions to the occurrence of clinically significant cardiac events. Dose modification may be required for those patients who develop AV block.
Elevations of lipase and/or amylase have occurred in patients receiving lorlatinib. Median time of occurrence of increase in serum lipase and amylase is 70 days (range: 7 days to 696 days) and 41 days (range: 7 days to 489 days), respectively. Risk of pancreatitis should be considered in patients receiving lorlatinib due to concomitant hypertriglyceridemia and/or a potential intrinsic mechanism. Patients should be monitored for lipase and amylase elevations prior to the start of lorlatinib treatment and regularly thereafter as clinically indicated.
Severe or life threatening pulmonary adverse drug reactions consistent with ILD/pneumonitis have occurred with lorlatinib. Any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough and fever) should be promptly evaluated for ILD/pneumonitis. Lorlatinib should be withheld and/or permanently discontinued based on severity.
Hypertension has been reported in patients receiving lorlatinib. Blood pressure should be controlled prior to the initiation of lorlatinib. Blood pressure should be monitored after 2 weeks and at least monthly thereafter during treatment with lorlatinib. Lorlatinib should be withheld and resumed at a reduced dose or permanently discontinued based on severity.
Hyperglycemia has occurred in patients receiving lorlatinib. Fasting serum glucose should be assessed prior to the initiation of lorlatinib and monitored periodically thereafter. Lorlatinib should be withheld and resumed at a reduced dose or permanently discontinued based on severity.
Concomitant use of any strong CYP3A inducer is contraindicated. Any strong CYP3A inducers have to be discontinued for at least 3 plasma half-lives of the strong CYP3A inducer before lorlatinib treatment is started. No clinically meaningful changes in liver function tests were seen in healthy subjects after receiving a combination of lorlatinib with the moderate CYP3A inducer modafinil.
Women of childbearing potential should be advised to avoid getting pregnant while receiving lorlatinib. Male fertility may be compromised during treatment with lorlatinib. Men should seek advice on effective fertility preservation before treatment.

​​​​​​​LORVIQUA® Efficacy

® Safety Profile
LORVIQUA® Dosing and Therapy
Click here for LORVIQUA® Prescribing Information

© 2021 Pfizer Pte Ltd. All rights reserved.

The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.